Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Vance

Clinical Cardiac Electrophysiology Jonesboro, AR Medical Doctor

NPI 1205001799 CMS profile 1381315

201 E Oak Ave, Jonesboro, AR 72401

Open in the dashboard

General payments

$8,712

250 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Vance of Jonesboro, AR is reported in the CMS Open Payments database as having received $8,712 across 250 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 31st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $786 26
2024 General $3,231 46
2023 General $757 27
2022 General $757 35
2021 General $1,212 32
2020 General $725 33
2019 General $1,245 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Vance
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to David Vance were reported at $786. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year David Vance Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,245 $2,361 $585–$8,260 $163
2020 $725 $993 $247–$4,351 $114
2021 $1,212 $1,185 $326–$4,739 $132
2022 $757 $2,073 $554–$6,789 $149
2023 $757 $2,568 $759–$8,159 $160
2024 $3,231 $2,557 $703–$7,403 $164
2025 $786 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $5,630 123 payments
  2. Biosense Webster, Inc. $887 40 payments
  3. Medtronic, Inc. $500 11 payments
  4. Boston Scientific Corporation $478 18 payments
  5. Janssen Pharmaceuticals, Inc $208 13 payments
  6. Novartis Pharmaceuticals Corporation $196 12 payments
  7. Atricure, Inc. $156 2 payments
  8. Daxor Corporation $93 1 payment
  9. Philips Electronics North America Corporation $90 2 payments
  10. Abiomed $80 3 payments
  11. Other $396 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,066 237 payments
  2. Travel and Lodging $1,646 13 payments
Products named General payments · program years 2019–2025
  1. AVEIR Cardiac Rhythm Management $2,169 20 payments
  2. Carto 3 $610 36 payments
  3. Assurity Pacemaker $510 17 payments
  4. Quadra Assura CRT Defibrillator $423 8 payments
  5. Confirm Rx $288 9 payments
  6. AVEIR Cardiac Rhythm Management $254 6 payments
  7. CardioMEMS HF System $215 2 payments
  8. XARELTO $208 13 payments
  9. ENTRESTO $184 11 payments
  10. ASSURITY $175 9 payments
  11. Other $3,724 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

3,784

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$837,551

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

50.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 951 $685,414
Xarelto Rivaroxaban Brand 132 $88,292
Entresto Sacubitril/Valsartan Brand 20 $16,199
Dofetilide Generic 91 $12,407
Sotalol Sotalol Hcl Brand 527 $7,465
Flecainide Acetate Generic 230 $7,260
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 19 $4,189
Amiodarone Hcl Generic 367 $3,360
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 101 $2,233
Metoprolol Succinate Generic 149 $1,567

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$199,088

Medicare's payments for the services billed

Medicare patients

861

Average age 78

Services billed

4,931

418 women, 443 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 72%
Ischemic heart disease 56%
Arthritis 51%
Heart failure 48%
Diabetes 42%
Chronic kidney disease 32%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

250 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record